Evonik launches EUDRACAP® colon functional capsules for the targeted delivery of oral drugs
- EUDRACAP® colon is the only functional, ready-to-fill capsule on the market targeting the ileo-colonic region
- New capsule is available in technical grade with a GMP product in development
- Further builds Evonik’s platform of system solutions for advanced oral drug delivery
Evonik is expanding its EUDRACAP® portfolio with a new functional, ready-to-fill capsule that enables the delivery of sensitive active ingredients to the ileo-colonic region. EUDRACAP® colon has been designed to meet the high customer need for a capsule that can deliver sensitive active ingredients, such as live biotherapeutic products (LBPs) to treat or prevent a wide range of diseases, to the ileo-colonic region. It is currently available in technical grade with a GMP-grade product in development. EUDRACAP® functional capsules help streamline the development of oral drugs, reducing complexity in formulation and increasing speed to market.
Evonik’s EUDRACAP® platform leverages EUDRAGIT® coatings for tailored oral drug release. For 70 years, Evonik has been providing EUDRAGIT® polymers as key ingredients in system solutions. These multi-component systems are tailored to unique and specific customer needs and through continuous innovation are driving a transformation to system solutions within Evonik’s life sciences division, Nutrition & Care.
“Drawing on decades of know-how, we are working with customers on new paths for ileo-colonic delivery. Our EUDRACAP® platform is a testament to strong innovation and growth and we are delighted to expand this portfolio,” said Axel Schroeder, Head of Oral Drug Delivery Solutions at Evonik.
EUDRACAP® colon can be used for the delivery of sensitive active ingredients such as live biotherapeutics, oral biologics, proteins, peptides and nucleotides (RNA). These actives are used in the formulation of innovative drugs for the treatment of severe conditions such as obesity, HIV, or Cystic Fibrosis, as well as for local delivery such as for colorectal cancer and infections.
EUDRACAP® colon is the latest addition to Evonik’s EUDRACAP® platform of innovations for oral drug delivery. In 2021, the company launched EUDRACAP® enteric to optimize gastric resistance, boost intestinal absorption and enhance bioavailability. Together with the EUDRACAP® Select line, Evonik provides tailor-made CDMO (Contract Development and Manufacturing Organization) services for customer requirements including a range of sizes, colors, and customized release profiles. In 2023, Evonik launched EUDRACAP® preclinic, for preclinical trials.
Over seven decades, EUDRAGIT® methacrylate polymers have established themselves as the industry standard with more than 23,000 patents and 10,000 scientific publications mentioning the EUDRAGIT® brand. Today, customers in over 80 countries use EUDRAGIT® polymers in their formulations for modified release.
Evonik Health Care has been a leader in advanced drug delivery for decades, supporting pharmaceutical companies worldwide with comprehensive services for the development of complex oral and parenteral drug products. This includes pharmaceutical excipients, formulation development and the manufacturing of clinical samples, as well as commercial drug products. Furthermore, the business serves as a CDMO for APIs and intermediates and has a strong focus on growth fields such as lipid-based mRNA and gene delivery and cell culture solutions for biopharma applications.
Want to learn more?
Company information
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023. Evonik goes far beyond chemistry to create innovative, profitable, and sustainable solutions for customers. Around 32,000 employees work together for a common purpose: We want to improve life today and tomorrow.
About Nutrition & Care
The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of €3.61 billion in 2023 with more than 5,600 employees.
Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.
